Delcath Systems Q1 revenue beats on Hepzato growth

Delcath Systems

07/05/2026 13:15

Overview

US interventional oncology firm's Q1 revenue rose 26% yr/yr, beating analyst expectations

Company posted Q1 net loss, with adjusted EBITDA down from prior year

Repurchased 316,023 shares for about $3 mln under buyback program

Outlook

Delcath Systems sees 2026 revenue of at least $100 mln

Company expects 2026 gross margins in the range of 84% to 87%

Delcath Systems projects positive adjusted EBITDA for 2026

Result Drivers

HEPZATO GROWTH - Q1 revenue growth driven by 36% increase in HEPZATO KIT volume and higher new patient starts

CHOPIN TRIAL IMPACT - Publication of CHOPIN Phase 2 trial results influenced prescribing patterns, supporting HEPZATO KIT uptake, per CEO Gerard Michel

HIGHER OPERATING EXPENSES - Increased R&D and commercial costs, including expanded clinical and commercial teams, contributed to lower profitability

Company press release: ID:nBw3KkbMja

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$24.99 mln
$23.38 mln (6 Analysts)
Q1 EPS
-$0.03
Q1 Net Income
-$1.07 mln
Q1 Gross Profit
$21.26 mln
Q1 Operating Expenses
$22.9 mln
Q1 Operating Income
-$1.64 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)